胰激肽原酶联合舒洛地特治疗糖尿病肾病的疗效及对氧化炎症状态、足细胞损伤的影响

Therapeutic Effect of Pancreatic Kallikrein Combined with Sulodexide on Diabetic Nephropathy and Its Effect on Oxidative Inflammation and Podocyte Injury

目的:探讨胰激肽原酶联合舒洛地特治疗糖尿病肾病(DN)的效果,分析患者氧化炎症状态、足细胞损伤程度的变化。方法:选取2016年8月-2018年8月在本院接受治疗的DN患者96例,按随机数字表法分为对照组(n=48,接受常规+胰激肽原酶治疗)、研究组(n=48,接受常规+胰激肽原酶+舒洛地特治疗)。对比两组近期疗效、血清氧化应激指标及炎症指标含量、尿液足细胞损伤指标(Podocin、Nephrin、Mindin)水平的差异。结果:治疗后,研究组治疗总有效率高于对照组(P<0.05);血清中高级氧化蛋白产物(AOPPs)、白介素-1(IL-1)、白介素-18(IL-18)含量均低于对照组(P<0.05),超氧化物歧化酶(SOD)含量高于对照组(P<0.05);尿液中Podocin、Nephrin、Mindin水平均低于对照组(P<0.05)。结论:胰激肽原酶联合舒洛地特用于DN治疗,有助于提升疗效并减轻机体氧化炎症及足细胞损伤。

Objective:To investigate the effect of Pancreatic Kallikrein combined with Sulodexide in the treatment of diabetic nephropathy(DN),and analyze the changes of oxidative inflammation and podocyte damage.Method:96 cases of DN patients from August 2016 to August 2018 were divided into control group(n=48,routine treatment + Pancreatic Kallikrein therapy),research group(n=48,routine treatment + Pancreatic Kallikrein + Sulodexide therapy)by random number table method.The short-term efficacy,serum contents of oxidative stress indicators and inflammatory indicators,indicators of urinary podocyte injury were compared between two groups.Result:After treatment,the total effective rate of the research group group was higher than that in control group(P<0.05),serum contents of advanced oxidative protein products(AOPPs),interleukin-1(IL-1),interleukin-18(IL-18)of the research group were lower than those in control group(P<0.05),content of superoxide dismutase(SOD)of the research group was higher than that in control group(P<0.05),levels of Podocin,Nephrin and Mindin in urine of the research group were lower than those in control group(P<0.05).Conclusion:Pancreatic Kallikrein combined with Sulodexide in the treatment of DN can improve the therapeutic effect and reduce oxidative inflammation and podocyte injury.